Methylethyltryptamine

Methylethyltryptamine
Clinical data
Other names	MET; N-Methyl-N-ethyltryptamine; N,N-MET
Routes of; administration	Oral; Vaporized/inhaled
Drug class	Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent
ATC code	None;
Pharmacokinetic data
Onset of action	Unknown
Duration of action	Unknown
Identifiers
	IUPAC name N-ethyl-2-(1H-indol-3-yl)-N-methylethan-1-amine;
CAS Number	5599-69-9 ;
PubChem CID	824845;
ChemSpider	720502 ;
UNII	4KX1J1D3RD;
CompTox Dashboard (EPA)	DTXSID901024010 ;
Chemical and physical data
Formula	C13H18N2
Molar mass	202.301 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cccc2c1c(c[nH]2)CCN(CC)C;
	InChI InChI=1S/C13H18N2/c1-3-15(2)9-8-11-10-14-13-7-5-4-6-12(11)13/h4-7,10,14H,3,8-9H2,1-2H3 ; Key:MYEGVMLMDWYPOA-UHFFFAOYSA-N ;
	(verify)

Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a psychedelic drug of the tryptamine family. It is taken orally or via inhalation.

The drug acts as an agonist of the serotonin 5-HT₂ receptors and to a lesser extent as a serotonin releasing agent. It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET).

MET appears to have been first described in the literature in 1981. It was only briefly mentioned in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved). The drug was encountered as a novel designer drug in Europe in 2014.